Open an account

Kalaris Therapeutics

KLRS · NASDAQ

$2.07+$0.16 (+8.38%)TodayMarket closed ·
Prev close $1.91

About KLRS

Kalaris Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for retinal diseases. The company is headquartered in Berkeley Heights, New Jersey and currently employs 20 full-time employees. The company went IPO on 2020-07-30. The firm is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).

Employees
20
Headquarters
Berkeley Heights, New Jersey
Listed
Jul 30, 2020
Sector
Health Care
Industry
Biotechnology
Website
kalaristx.com

KLRS key statistics

Market cap
45.21M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
84.80K
Volume
51.41K
Open price
$1.90
High today
$2.10
Low today
$1.90
52 Week high
$11.88
52 Week low
$1.87

Kalaris Therapeutics (KLRS) at a glance

As of Oct 20, 2026, Kalaris Therapeutics (KLRS) shares are priced at $2.07, giving the company a market cap of 45.21M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.90 and $2.10. The current price is 8.9% above the day's low and 1.4% below its high.

Volume so far is 51.41K shares, below the average of 84.80K shares a day.

Over the past year Kalaris Therapeutics has ranged from $1.87 to $11.88, and now sits 2% of the way up that range.

Kalaris Therapeutics met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.48 per share against an estimate of -$0.5049.

KLRS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 16.4% on average.

  1. Q1 FY24: reported -$5.98 per share against an estimate of -$3.68
  2. Q2 FY24: reported -$1.15 per share against an estimate of -$2.46
  3. Q1 FY25: reported -$2.52 per share against an estimate of -$0.7905
  4. Q2 FY25: reported -$0.61 per share against an estimate of -$0.5304
  5. Q3 FY25: reported -$0.64 per share against an estimate of -$0.6659
  6. Q4 FY25: reported -$0.51 per share against an estimate of -$0.5421
  7. Q1 FY26: reported -$0.46 per share against an estimate of -$0.5336
  8. Q2 FY26: reported -$0.48 per share against an estimate of -$0.5049

KLRS news

  • Press releaseGlobe Newswire

    Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates

  • Vandana Singh

    Why Is Kalaris Therapeutics Stock Gaining Friday?

  • Press releaseGlobe Newswire

    Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates

  • Press releaseGlobe Newswire

    Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.